Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 164 entries
Sorted by: Best Match Show Resources per page
Rhabdomyolysis in a patient taking nebivolol.

Kidney research and clinical practice

Kim YJ, Kim HR, Jeon HJ, Ju HJ, Chung S, Choi DE, Lee KW, Na KR.
PMID: 27668163
Kidney Res Clin Pract. 2016 Sep;35(3):182-6. doi: 10.1016/j.krcp.2015.09.003. Epub 2016 Jan 22.

β Blockers such as propranolol and labetalol are known to induce toxic myopathy because of their partial β2 adrenoceptor agonistic effect. Nebivolol has the highest β1 receptor affinity among β blockers, and it has never been reported to induce...

Cite
Kim YJ, Kim HR, Jeon HJ, et al. Rhabdomyolysis in a patient taking nebivolol. Kidney Res Clin Pract. 2016;35(3):182-6doi: 10.1016/j.krcp.2015.09.003.
Kim, Y. J., Kim, H. R., Jeon, H. J., Ju, H. J., Chung, S., Choi, D. E., Lee, K. W., & Na, K. R. (2016). Rhabdomyolysis in a patient taking nebivolol. Kidney research and clinical practice, 35(3), 182-6. https://doi.org/10.1016/j.krcp.2015.09.003
Kim, Ye Jin, et al. "Rhabdomyolysis in a patient taking nebivolol." Kidney research and clinical practice vol. 35,3 (2016): 182-6. doi: https://doi.org/10.1016/j.krcp.2015.09.003
Kim YJ, Kim HR, Jeon HJ, Ju HJ, Chung S, Choi DE, Lee KW, Na KR. Rhabdomyolysis in a patient taking nebivolol. Kidney Res Clin Pract. 2016 Sep;35(3):182-6. doi: 10.1016/j.krcp.2015.09.003. Epub 2016 Jan 22. PMID: 27668163; PMCID: PMC5025462.
Copy Download .nbib Format: NLM
Monotherapy with labetalol for hypertensive patients with normal and impaired renal function.

British journal of clinical pharmacology

Thompson FD, Joekes AM, Hussein MM.
PMID: 26635153
Br J Clin Pharmacol. 1979 Apr;8:129S-33S. doi: 10.1111/j.1365-2125.1979.tb04767.x.

1 Labetalol was given to 41 hypertensive patients in a divided dosage of 150-2,400 mg daily for periods ranging from 1-64 months. 2 Monotherapy with labetalol was adequate in 12 out of 19 patients with essential hypertension and in...

Cite
Thompson FD, Joekes AM, Hussein MM. Monotherapy with labetalol for hypertensive patients with normal and impaired renal function. Br J Clin Pharmacol. 1979;8:129S-33Sdoi: 10.1111/j.1365-2125.1979.tb04767.x.
Thompson, F. D., Joekes, A. M., & Hussein, M. M. (1979). Monotherapy with labetalol for hypertensive patients with normal and impaired renal function. British journal of clinical pharmacology, 8129S-33S. https://doi.org/10.1111/j.1365-2125.1979.tb04767.x
Thompson, F D, et al. "Monotherapy with labetalol for hypertensive patients with normal and impaired renal function." British journal of clinical pharmacology vol. 8 (1979): 129S-33S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04767.x
Thompson FD, Joekes AM, Hussein MM. Monotherapy with labetalol for hypertensive patients with normal and impaired renal function. Br J Clin Pharmacol. 1979 Apr;8:129S-33S. doi: 10.1111/j.1365-2125.1979.tb04767.x. PMID: 26635153.
Copy Download .nbib Format: NLM
A comparative study of methyldopa and labetalol in the treatment of hypertension.

British journal of clinical pharmacology

Sanders GL, Davies DM, Gales GM, Rao JG, Rawlins MD, Routledge PA.
PMID: 26635157
Br J Clin Pharmacol. 1979 Apr;8:149S-51S. doi: 10.1111/j.1365-2125.1979.tb04771.x.

1 Twenty patients with essential hypertension completed a double-blind, dose-tritrated, cross-over comparison of methyldopa and labetalol. 2 Average lying BPs (systolic/diastolic) were reduced by 28/15 mmHg with methyldopa and by 23/15 mmHg with labetalol. 3 Average standing BPs (systolic/diastolic)...

Cite
Sanders GL, Davies DM, Gales GM, et al. A comparative study of methyldopa and labetalol in the treatment of hypertension. Br J Clin Pharmacol. 1979;8:149S-51Sdoi: 10.1111/j.1365-2125.1979.tb04771.x.
Sanders, G. L., Davies, D. M., Gales, G. M., Rao, J. G., Rawlins, M. D., & Routledge, P. A. (1979). A comparative study of methyldopa and labetalol in the treatment of hypertension. British journal of clinical pharmacology, 8149S-51S. https://doi.org/10.1111/j.1365-2125.1979.tb04771.x
Sanders, G L, et al. "A comparative study of methyldopa and labetalol in the treatment of hypertension." British journal of clinical pharmacology vol. 8 (1979): 149S-51S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04771.x
Sanders GL, Davies DM, Gales GM, Rao JG, Rawlins MD, Routledge PA. A comparative study of methyldopa and labetalol in the treatment of hypertension. Br J Clin Pharmacol. 1979 Apr;8:149S-51S. doi: 10.1111/j.1365-2125.1979.tb04771.x. PMID: 26635157.
Copy Download .nbib Format: NLM
A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension.

British journal of clinical pharmacology

McNeil JJ, Louis WJ.
PMID: 26635160
Br J Clin Pharmacol. 1979 Apr;8:163S-6S. doi: 10.1111/j.1365-2125.1979.tb04774.x.

1 This study was designed to compare in a double-blind randomized crossover trial, atenolol, labetalol, metoprolol and pindolol. Considerable differences in dose (atenolol 138 +/- 13 mg daily; labetalol 308 +/- 34 mg daily; metoprolol 234 +/- 22 mg...

Cite
McNeil JJ, Louis WJ. A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Br J Clin Pharmacol. 1979;8:163S-6Sdoi: 10.1111/j.1365-2125.1979.tb04774.x.
McNeil, J. J., & Louis, W. J. (1979). A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. British journal of clinical pharmacology, 8163S-6S. https://doi.org/10.1111/j.1365-2125.1979.tb04774.x
McNeil, J J, and Louis, W J. "A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension." British journal of clinical pharmacology vol. 8 (1979): 163S-6S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04774.x
McNeil JJ, Louis WJ. A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Br J Clin Pharmacol. 1979 Apr;8:163S-6S. doi: 10.1111/j.1365-2125.1979.tb04774.x. PMID: 26635160.
Copy Download .nbib Format: NLM
A multicentre open trial of labetalol in New Zealand.

British journal of clinical pharmacology

Sanders GL, Davies DM, Gales GM, Rao JG, Rawlins MD, Routledge PA.
PMID: 26635163
Br J Clin Pharmacol. 1979 Apr;8:179S-82S. doi: 10.1111/j.1365-2125.1979.tb04777.x.

1 In a multicentre open trial, labetalol was given to 128 patients in ten centres. Forty-three patients had not previously received antihypertensive therapy; the remainder (85 patients) had been on antihypertensive therapy with either unsatisfactory BP control or troublesome...

Cite
Sanders GL, Davies DM, Gales GM, et al. A multicentre open trial of labetalol in New Zealand. Br J Clin Pharmacol. 1979;8:179S-82Sdoi: 10.1111/j.1365-2125.1979.tb04777.x.
Sanders, G. L., Davies, D. M., Gales, G. M., Rao, J. G., Rawlins, M. D., & Routledge, P. A. (1979). A multicentre open trial of labetalol in New Zealand. British journal of clinical pharmacology, 8179S-82S. https://doi.org/10.1111/j.1365-2125.1979.tb04777.x
Sanders, G L, et al. "A multicentre open trial of labetalol in New Zealand." British journal of clinical pharmacology vol. 8 (1979): 179S-82S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04777.x
Sanders GL, Davies DM, Gales GM, Rao JG, Rawlins MD, Routledge PA. A multicentre open trial of labetalol in New Zealand. Br J Clin Pharmacol. 1979 Apr;8:179S-82S. doi: 10.1111/j.1365-2125.1979.tb04777.x. PMID: 26635163.
Copy Download .nbib Format: NLM
Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings.

British journal of clinical pharmacology

Pearson RM, Griffith DN, Woollard M, James IM, Havard CW.
PMID: 26635166
Br J Clin Pharmacol. 1979 Apr;8:195S-8S. doi: 10.1111/j.1365-2125.1979.tb04780.x.

1 Diazoxide 300 mg and labetalol 150 mg were each injected intravenously on separate occasions into five patients with essentail hypertension. The reduction in BP caused by labetalol was slightly greater than that produced by diazoxide. 2 In contrast...

Cite
Pearson RM, Griffith DN, Woollard M, et al. Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings. Br J Clin Pharmacol. 1979;8:195S-8Sdoi: 10.1111/j.1365-2125.1979.tb04780.x.
Pearson, R. M., Griffith, D. N., Woollard, M., James, I. M., & Havard, C. W. (1979). Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings. British journal of clinical pharmacology, 8195S-8S. https://doi.org/10.1111/j.1365-2125.1979.tb04780.x
Pearson, R M, et al. "Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings." British journal of clinical pharmacology vol. 8 (1979): 195S-8S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04780.x
Pearson RM, Griffith DN, Woollard M, James IM, Havard CW. Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings. Br J Clin Pharmacol. 1979 Apr;8:195S-8S. doi: 10.1111/j.1365-2125.1979.tb04780.x. PMID: 26635166.
Copy Download .nbib Format: NLM
Use of labetalol in the treatment of severe hypertension during pregnancy.

British journal of clinical pharmacology

Michael CA.
PMID: 26635169
Br J Clin Pharmacol. 1979 Apr;8:211S-5S. doi: 10.1111/j.1365-2125.1979.tb04783.x.

1 Labetalol, a hypotensive agent combining alpha- and beta-adrenoceptor antagonist properties, was used to treat severe hypertensive disease complicating pregnancy. 2 Effective reduction in BP was achieved in all but 3 of the 25 patients treated. Careful monitoring of...

Cite
Michael CA. Use of labetalol in the treatment of severe hypertension during pregnancy. Br J Clin Pharmacol. 1979;8:211S-5Sdoi: 10.1111/j.1365-2125.1979.tb04783.x.
Michael, C. A. (1979). Use of labetalol in the treatment of severe hypertension during pregnancy. British journal of clinical pharmacology, 8211S-5S. https://doi.org/10.1111/j.1365-2125.1979.tb04783.x
Michael, C A. "Use of labetalol in the treatment of severe hypertension during pregnancy." British journal of clinical pharmacology vol. 8 (1979): 211S-5S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04783.x
Michael CA. Use of labetalol in the treatment of severe hypertension during pregnancy. Br J Clin Pharmacol. 1979 Apr;8:211S-5S. doi: 10.1111/j.1365-2125.1979.tb04783.x. PMID: 26635169.
Copy Download .nbib Format: NLM
Use of labetalol and methyldopa in pregnancy-induced hypertension.

British journal of clinical pharmacology

Lamming GD, Symonds EB.
PMID: 26635170
Br J Clin Pharmacol. 1979 Apr;8:217S-22S. doi: 10.1111/j.1365-2125.1979.tb04784.x.

1 Nineteen pregnant patients whose mean arterial pressure (MAP) was persistently greater than or equal to 103.3 mmHg were given labetalol or methyldopa. 2 Singificant falls (P less than 0.001) in BP only occurred in the group treated with...

Cite
Lamming GD, Symonds EB. Use of labetalol and methyldopa in pregnancy-induced hypertension. Br J Clin Pharmacol. 1979;8:217S-22Sdoi: 10.1111/j.1365-2125.1979.tb04784.x.
Lamming, G. D., & Symonds, E. B. (1979). Use of labetalol and methyldopa in pregnancy-induced hypertension. British journal of clinical pharmacology, 8217S-22S. https://doi.org/10.1111/j.1365-2125.1979.tb04784.x
Lamming, G D, and Symonds, E B. "Use of labetalol and methyldopa in pregnancy-induced hypertension." British journal of clinical pharmacology vol. 8 (1979): 217S-22S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04784.x
Lamming GD, Symonds EB. Use of labetalol and methyldopa in pregnancy-induced hypertension. Br J Clin Pharmacol. 1979 Apr;8:217S-22S. doi: 10.1111/j.1365-2125.1979.tb04784.x. PMID: 26635170.
Copy Download .nbib Format: NLM
Labetalol infusion in acute myocardial infarction with systemic hypertension.

British journal of clinical pharmacology

Marx PG, Reid DS.
PMID: 26635173
Br J Clin Pharmacol. 1979 Apr;8:233S-8S. doi: 10.1111/j.1365-2125.1979.tb04787.x.

1 Fifteen patients with suspected acute myocardial infarction and systemic BP of greater than 160/110 mmHg were treated with an incremental infusion of labetalol. 2 Systemic BPs were safely and effectively lowered to less than 130 mm Hg systolic...

Cite
Marx PG, Reid DS. Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol. 1979;8:233S-8Sdoi: 10.1111/j.1365-2125.1979.tb04787.x.
Marx, P. G., & Reid, D. S. (1979). Labetalol infusion in acute myocardial infarction with systemic hypertension. British journal of clinical pharmacology, 8233S-8S. https://doi.org/10.1111/j.1365-2125.1979.tb04787.x
Marx, P G, and Reid, D S. "Labetalol infusion in acute myocardial infarction with systemic hypertension." British journal of clinical pharmacology vol. 8 (1979): 233S-8S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04787.x
Marx PG, Reid DS. Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol. 1979 Apr;8:233S-8S. doi: 10.1111/j.1365-2125.1979.tb04787.x. PMID: 26635173.
Copy Download .nbib Format: NLM
Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

British journal of clinical pharmacology

Prichard BN, Richards DA.
PMID: 26635174
Br J Clin Pharmacol. 1979 Apr;8:239S-44S. doi: 10.1111/j.1365-2125.1979.tb04788.x.

No abstract available.

Cite
Prichard BN, Richards DA. Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. Br J Clin Pharmacol. 1979;8:239S-44Sdoi: 10.1111/j.1365-2125.1979.tb04788.x.
Prichard, B. N., & Richards, D. A. (1979). Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. British journal of clinical pharmacology, 8239S-44S. https://doi.org/10.1111/j.1365-2125.1979.tb04788.x
Prichard, B N, and Richards, D A. "Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium." British journal of clinical pharmacology vol. 8 (1979): 239S-44S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04788.x
Prichard BN, Richards DA. Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. Br J Clin Pharmacol. 1979 Apr;8:239S-44S. doi: 10.1111/j.1365-2125.1979.tb04788.x. PMID: 26635174.
Copy Download .nbib Format: NLM
PHEOCHROMOCYTOMA DURING PREGNANCY-2 CASE REPORTS.

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology

Yasui M, Hattori Y, Uemura K, Ishida H, Teranishi JI, Yumura Y, Miyoshi Y, Kondo K, Uemura H.
PMID: 29070738
Nihon Hinyokika Gakkai Zasshi. 2016;107(4):245-250. doi: 10.5980/jpnjurol.107.245.

(Introduction) A pheochromocytoma diagnosed during pregnancy is rare, and also its fetal and maternal mortality is high if undiagnosed. We report two cases with successful pregnancy outcome with pheochromocytoma. (Case 1) A 31-years-old previously healthy woman presented at 19...

Cite
Yasui M, Hattori Y, Uemura K, et al. PHEOCHROMOCYTOMA DURING PREGNANCY-2 CASE REPORTS. Nihon Hinyokika Gakkai Zasshi. 2016;107(4):245-250doi: 10.5980/jpnjurol.107.245.
Yasui, M., Hattori, Y., Uemura, K., Ishida, H., Teranishi, J. I., Yumura, Y., Miyoshi, Y., Kondo, K., & Uemura, H. (2016). PHEOCHROMOCYTOMA DURING PREGNANCY-2 CASE REPORTS. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 107(4), 245-250. https://doi.org/10.5980/jpnjurol.107.245
Yasui, Masato, et al. "PHEOCHROMOCYTOMA DURING PREGNANCY-2 CASE REPORTS." Nihon Hinyokika Gakkai zasshi. The japanese journal of urology vol. 107,4 (2016): 245-250. doi: https://doi.org/10.5980/jpnjurol.107.245
Yasui M, Hattori Y, Uemura K, Ishida H, Teranishi JI, Yumura Y, Miyoshi Y, Kondo K, Uemura H. PHEOCHROMOCYTOMA DURING PREGNANCY-2 CASE REPORTS. Nihon Hinyokika Gakkai Zasshi. 2016;107(4):245-250. doi: 10.5980/jpnjurol.107.245. Japanese. PMID: 29070738.
Copy Download .nbib Format: NLM
Posterior reversible encephalopathy syndrome in a patient of organophosphate poisoning.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine

Phatake R, Desai S, Lodaya M, Deshpande S, Tankasali N.
PMID: 24872658
Indian J Crit Care Med. 2014 Apr;18(4):250-2. doi: 10.4103/0972-5229.130580.

A 32-year-old male presented with a history of consuming some organophosphorous compound with suicidal intention. He was treated with atropine, pralidoxime, ventilator support. During stay patient had persistent irritability, tachycardiaand hypertension despite sedation and labetalol infusion. He developed headache,...

Cite
Phatake R, Desai S, Lodaya M, et al. Posterior reversible encephalopathy syndrome in a patient of organophosphate poisoning. Indian J Crit Care Med. 2014;18(4):250-2doi: 10.4103/0972-5229.130580.
Phatake, R., Desai, S., Lodaya, M., Deshpande, S., & Tankasali, N. (2014). Posterior reversible encephalopathy syndrome in a patient of organophosphate poisoning. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 18(4), 250-2. https://doi.org/10.4103/0972-5229.130580
Phatake, Rajesh, et al. "Posterior reversible encephalopathy syndrome in a patient of organophosphate poisoning." Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine vol. 18,4 (2014): 250-2. doi: https://doi.org/10.4103/0972-5229.130580
Phatake R, Desai S, Lodaya M, Deshpande S, Tankasali N. Posterior reversible encephalopathy syndrome in a patient of organophosphate poisoning. Indian J Crit Care Med. 2014 Apr;18(4):250-2. doi: 10.4103/0972-5229.130580. PMID: 24872658; PMCID: PMC4033862.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 164 entries